A brief review of exercise, bipolar disorder, and mechanistic pathways
Daniel Thomson, Alyna Turner, Sue Lauder, Margaret E Gigler, Lesley Berk, Ajeet B Singh, Julie A Pasco, Michael Berk, Louisa Sylvia
Frontiers in Psychology | FRONTIERS MEDIA SA | Published : 2015
Despite evidence that exercise has been found to be effective in the treatment of depression, it is unclear whether these data can be extrapolated to bipolar disorder. Available evidence for bipolar disorder is scant, with no existing randomized controlled trials having tested the impact of exercise on depressive, manic or hypomanic symptomatology. Although exercise is often recommended in bipolar disorder, this is based on extrapolation from the unipolar literature, theory and clinical expertise and not empirical evidence. In addition, there are currently no available empirical data on program variables, with practical implications on frequency, intensity and type of exercise derived from u..View full abstract
Awarded by NHMRC Senior Principal Research Fellowship
No funding has been received to support this study, Ajeet B. Singh is a casual speaker for Servier Australia, Pfizer Australia, and Lundbeck Australia. Julie A. Pasco has received grant/research support from the NHMRC, Perpetual, Amgen (Europe) GmBH, and BUPA Foundation and has received speaker fees from Amgen and Sanofi Aventis. Michael Berk is supported by a NHMRC Senior Principal Research Fellowship 1059660 and has received Grant/Research Support from the NTH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Rotary Health, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Meat and Livestock Board, Organon, Novartis, Mayne Pharma, Servier and Woolworths, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth, and served as a consultant to Astra Zeneca, Bioadvaraex, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck Merck and Servier. Louisa Sylvia was a shareholder in Concordant Rater Systems and serves as a consultant for United Biosource Corporation, Clinical Trials Network and Institute, Clintara. She receives royalties from New Harbinger.